Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
Davood YadegaryniaAmirreza KeyvanfarHossein KeyvaniShabnam TehraniShahnaz SaliSara AbolghasemiPublished in: Vaccine (2024)
The study protocol was approved by the Iranian Registry of Clinical Trials (IRCT20210901052358N5).